- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02950857
A Study of EPEG in Beta Thalassemia Patients
A Phase Ib, Open-label, Repeat Dose, Study of EPEG in Beta Thalassemia Patients With Non-transfusion Dependent Thalassemia (β NTDT)
Study Overview
Detailed Description
Following the provision of informed consent, screening visit procedures to be performed will include: a detailed medical history (including concomitant medications), physical exam, vital signs (non-invasive systolic and diastolic arterial blood pressure, heart rate, and respiratory rate, temperature, and oxygen saturation by pulse oximetry,), laboratory testing of blood samples collections for safety (hematology and chemistry), and urinalysis (dipstick and microscopy, if necessary). A serum pregnancy test for all female patients (of child-bearing potential) will be measured during the Screening Visit. Urine pregnancy test for all female patients (of child-bearing potential) will be measured at each dosing visit prior to dosing.
Eligible patients will receive either subcutaneous injection of EPEG (0.9 µg/kg, 1.2 µg/kg, and 1.5 µg/kg,) for four weeks followed by follow up for 5-6 weeks after 4th dose of IP.
Vital signs will be recorded for study documentation at 1 hour after dosing and at discharge of the day (to occur 2 hours after the time of dosing). All patients will receive standard of care as per investigative site standard practice.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chiang Mai, Thailand, 50200
- Faculty of Medicine, Chiang Mai University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- Age 18 - 65 years of age
- Confirmed diagnosis of Non-Transfusion Dependent β-thalassemia (β-NTDT)
- Hemoglobin 6.0-10.0 g/dL
- Signed and dated informed written consent by the subject
- Able to receive subcutaneous injections of study drug
- Female patients must be non-lactating
- Female patients of reproductive potential must have a negative serum pregnancy (β-HCG) test at screening.
Exclusion Criteria:
- In the judgment of the investigator the patient is not a good candidate for the study
- Blood transfusion within the last 30 days
Any of the following medical conditions:
- Severe kidney insufficiency, defined as use of hemodialysis or serum creatinine at levels greater than 2.5 mg/dL at the time of screening
- Cardiac disease with adjustment of cardiac medications in the 60 days before study entry
- Symptomatic coronary artery disease, as indicated by a history of chest pain, angina, claudication, or surgery to treat coronary artery disease in the 1 year before study entry
- Stroke, defined as a new focal neurological deficit lasting more than 24 hours in the 45 days before study entry
- New diagnosis of pulmonary embolism by ventilation-perfusion scan, angiography, or any other technique in the 90 days before study entry
- History of retinal detachment or retinal hemorrhage in the 180 days before study entry
- Use of nitrate-based vasodilators, prostacyclin (inhaled, subcutaneous, or intravenous)
- Acute asthma exacerbation requiring use of prednisone in the 60 days before study entry
- Initiation or dosage increase of calcium channel blockers in the 30 days before study entry
- Initiation of any other cardiac or pulmonary medication in the 90 days before study entry
- Presence of any other condition, which in the opinion of the investigator, would make the person unsuitable for enrollment or could interfere with compliance in the study, including but not limited to alcohol or drug abuse
- Any prior treatment with Erythropoiesis-stimulating Agents (ESA) within 90 days of study treatment;
- History of hypersensitivity to erythropoietin or any related drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EPEG (pegylated erythropoietin) - 0.9 µg/kg
Four weekly subcutaneous injections of 0.9 µg/kg EPEG
|
(Pegylated erythropoeitin)
|
Experimental: EPEG (pegylated erythropoietin) - 1.2 µg/kg
Four weekly subcutaneous injections of 1.2 µg/kg EPEG
|
(Pegylated erythropoeitin)
|
Experimental: EPEG (pegylated erythropoietin) - 1.5 µg/kg
Four weekly subcutaneous injections of 1.5 µg/kg EPEG
|
(Pegylated erythropoeitin)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants in each treatment arm with abnormal laboratory values and/or adverse events that are related to treatment.
Time Frame: 60 days
|
Safety of treatment as determined by changes in vital signs, chest X-Ray, electrocardiographic, biochemical, hematological, and urinalysis measures, and reported adverse events
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the Hemoglobin from Baseline to the Final Visit
Time Frame: 60 Days
|
60 Days
|
A mean increase in Hematocrit (Hct) from Baseline to the Final Visit
Time Frame: 60 Days
|
60 Days
|
A mean increase in reticulocyte count from Baseline to the Final Visit
Time Frame: 60 Days
|
60 Days
|
Change in clinical signs and symptoms of β-NTDT from Baseline to the Final Visit
Time Frame: 60 Days
|
60 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Rosa Real, MD, Prolong Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PETH-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Beta-Thalassemia
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
Ionis Pharmaceuticals, Inc.TerminatedBeta Thalassemia IntermediaAustralia, Thailand, Greece, Lebanon, Turkey
-
Children's Hospital of PhiladelphiaNot yet recruiting
-
Bristol-Myers SquibbRecruiting
-
Assiut UniversityRecruiting
-
CelgeneAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...RecruitingBeta-ThalassemiaUnited States, Turkey, Italy, Thailand, Germany, Greece, China, India, Lebanon
-
Vertex Pharmaceuticals IncorporatedCRISPR TherapeuticsActive, not recruitingHematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-ThalassemiaUnited States, United Kingdom, Canada, Germany, Italy
Clinical Trials on EPEG
-
National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
University of California, DavisNovartisCompletedUnspecified Adult Solid Tumor, Protocol Specific | Extensive Stage Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedExtensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung CancerUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Teratoma | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor | Childhood Embryonal Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Extragonadal Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland